In the years postapproval of rilonacept in RP, second-line management of patients failing aspirin/NSAIDs/colchicine has shifted increasingly toward IL-1 pathway inhibition rather than chronic corticosteroids. This evidence concerns the gene IL1A and retinitis pigmentosa 1.